171 related articles for article (PubMed ID: 35689468)
21. PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays.
Munari E; Zamboni G; Lunardi G; Marconi M; Brunelli M; Martignoni G; Netto GJ; Quatrini L; Vacca P; Moretta L; Bogina G
Hum Pathol; 2019 Aug; 90():54-59. PubMed ID: 31121194
[TBL] [Abstract][Full Text] [Related]
22. c-mos immunoreactivity aids in the diagnosis of gestational trophoblastic lesions.
Xue WC; Khoo US; Ngan HY; Chan KY; Ip PP; Tsao SW; Cheung AN
Int J Gynecol Pathol; 2004 Apr; 23(2):145-50. PubMed ID: 15084843
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K
Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of ASPP1 in gestational trophoblastic disease: correlation with hypermethylation, apoptotic activity and clinical outcome.
Mak VC; Lee L; Siu MK; Wong OG; Lu X; Ngan HY; Wong ES; Cheung AN
Mod Pathol; 2011 Apr; 24(4):522-32. PubMed ID: 21102414
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemistry in the diagnosis of the gestational trophoblastic disease.
Lösch A; Kainz C
Acta Obstet Gynecol Scand; 1996 Sep; 75(8):753-6. PubMed ID: 8906012
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.
Parra ER; Villalobos P; Mino B; Rodriguez-Canales J
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):83-93. PubMed ID: 28719380
[TBL] [Abstract][Full Text] [Related]
27. Expression of c-erbB2 in gestational trophoblastic disease and its clinical significance.
Wang Y; Cao Y; Sun Y
J Huazhong Univ Sci Technolog Med Sci; 2002; 22(2):123-5. PubMed ID: 12658752
[TBL] [Abstract][Full Text] [Related]
28. Harmonization of programmed death-ligand 1 immunohistochemistry and mRNA expression scoring in metastatic melanoma: a multicentre analysis.
Darmon-Novello M; Adam J; Lamant L; Battistella M; Ortonne N; Balme B; de la Fouchardière A; Chaltiel L; Gerard E; Franchet C; Vergier B
Histopathology; 2022 Jun; 80(7):1091-1101. PubMed ID: 35322452
[TBL] [Abstract][Full Text] [Related]
29. p57(KIP2) immunohistochemical staining of gestational trophoblastic tumours does not identify the type of the causative pregnancy.
Sebire NJ; Rees HC; Peston D; Seckl MJ; Newlands ES; Fisher RA
Histopathology; 2004 Aug; 45(2):135-41. PubMed ID: 15279631
[TBL] [Abstract][Full Text] [Related]
30. Programmed cell death ligand-1 (PD-L1) expression in extrahepatic biliary tract cancers: a comparative study using 22C3, SP263 and E1L3N anti-PD-L1 antibodies.
Ahn S; Lee Y; Kim JW; Lee JC; Hwang JH; Yoon YS; Cho JY; Han HS; Choi Y; Kim H
Histopathology; 2019 Oct; 75(4):526-536. PubMed ID: 31081949
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Hirsch FR; McElhinny A; Stanforth D; Ranger-Moore J; Jansson M; Kulangara K; Richardson W; Towne P; Hanks D; Vennapusa B; Mistry A; Kalamegham R; Averbuch S; Novotny J; Rubin E; Emancipator K; McCaffery I; Williams JA; Walker J; Longshore J; Tsao MS; Kerr KM
J Thorac Oncol; 2017 Feb; 12(2):208-222. PubMed ID: 27913228
[TBL] [Abstract][Full Text] [Related]
32. Apoptotic index for prediction of postmolar gestational trophoblastic neoplasia.
Braga A; Maestá I; Rocha Soares R; Elias KM; Custódio Domingues MA; Barbisan LF; Berkowitz RS
Am J Obstet Gynecol; 2016 Sep; 215(3):336.e1-336.e12. PubMed ID: 27094961
[TBL] [Abstract][Full Text] [Related]
33. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study.
Cerbelli B; Girolami I; Eccher A; Costarelli L; Taccogna S; Scialpi R; Benevolo M; Lucante T; Luigi Alò P; Stella F; Gemma Pignataro M; Fadda G; Perrone G; D'Amati G; Martini M
Histopathology; 2022 Jan; 80(2):397-406. PubMed ID: 34496080
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.
Hodgson A; Slodkowska E; Jungbluth A; Liu SK; Vesprini D; Enepekides D; Higgins K; Katabi N; Xu B; Downes MR
Am J Surg Pathol; 2018 Aug; 42(8):1059-1066. PubMed ID: 29750666
[TBL] [Abstract][Full Text] [Related]
35. Matrix metalloproteinases and their inhibitors in gestational trophoblastic diseases and normal placenta.
Vegh GL; Selcuk Tuncer Z; Fulop V; Genest DR; Mok SC; Berkowitz RS
Gynecol Oncol; 1999 Nov; 75(2):248-53. PubMed ID: 10525381
[TBL] [Abstract][Full Text] [Related]
36. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.
Adam J; Le Stang N; Rouquette I; Cazes A; Badoual C; Pinot-Roussel H; Tixier L; Danel C; Damiola F; Damotte D; Penault-Llorca F; Lantuéjoul S
Ann Oncol; 2018 Apr; 29(4):953-958. PubMed ID: 29351573
[TBL] [Abstract][Full Text] [Related]
37. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
[TBL] [Abstract][Full Text] [Related]
38. Expression patterns of ERVWE1/Syncytin-1 and other placentally expressed human endogenous retroviruses along the malignant transformation process of hydatidiform moles.
Bolze PA; Patrier S; Cheynet V; Oriol G; Massardier J; Hajri T; Guillotte M; Bossus M; Sanlaville D; Golfier F; Mallet F
Placenta; 2016 Mar; 39():116-24. PubMed ID: 26992684
[TBL] [Abstract][Full Text] [Related]
39. Cell proliferative activity and mutation of P53 suppressor gene in human gestational trophoblastic disease.
Persaud V; Ganjei P; Nadji M
West Indian Med J; 1993 Dec; 42(4):142-3. PubMed ID: 7909185
[TBL] [Abstract][Full Text] [Related]
40. c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma.
Fulop V; Mok SC; Genest DR; Szigetvari I; Cseh I; Berkowitz RS
J Reprod Med; 1998 Feb; 43(2):101-10. PubMed ID: 9513871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
